SV

Street Verdict

Analyst Scorecard

A record of what Riyank Arora said publicly, with the source. Not advice.

Pending — not yet graded
“Bullish on Piramal Pharma for the short term, recommending a buy at CMP ₹232 with a target of ₹250 and a stop-loss at ₹220. The stock exhibits bullish momentum with strong buying interest around ₹220 and improving RSI, suggesting potential for further gains if it breaks above ₹250.”

Riyank Arora’s track record (trackable calls only): 124 graded calls · 95% CI 23–39%

Piramal Pharma LtdBullishCalled 14 Jan 2025
Verdict:PENDING

How this call is judged

A call is judged on closing prices only: a close at its target is a hit and a close at its stop is a miss. A call that states an entry starts at the first close that reaches it; if none does in the days allowed, it was never triggered, is not graded and counts toward no hit rate.

Entry: ₹232, as stated.

Target ₹250, stop ₹220, as stated.

Window: 30 days, from the call's own horizon word ("for the short term").

Waiting for a close to reach the entry.

This call has no verdict yet — it is graded HIT or MISS against real price data once a close decides it. Save it above to find it again from your profile.

Tracking Piramal Pharma Ltd since this call

1-year tracking window
Read the original articleSee Riyank Arora’s full track record